CWA Asset Management Group LLC Purchases New Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

CWA Asset Management Group LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,764 shares of the medical research company's stock, valued at approximately $1,091,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BDF Gestion acquired a new position in Thermo Fisher Scientific during the second quarter worth about $6,368,000. Nisa Investment Advisors LLC raised its position in shares of Thermo Fisher Scientific by 6.2% in the third quarter. Nisa Investment Advisors LLC now owns 140,708 shares of the medical research company's stock valued at $87,093,000 after buying an additional 8,180 shares during the last quarter. Lord Abbett & CO. LLC raised its position in shares of Thermo Fisher Scientific by 1.9% in the first quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company's stock valued at $45,478,000 after buying an additional 1,480 shares during the last quarter. Seven Eight Capital LP acquired a new position in shares of Thermo Fisher Scientific in the first quarter valued at approximately $1,161,000. Finally, ORG Partners LLC grew its holdings in Thermo Fisher Scientific by 216.6% in the second quarter. ORG Partners LLC now owns 1,640 shares of the medical research company's stock valued at $890,000 after purchasing an additional 1,122 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Sanford C. Bernstein decreased their price objective on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a "market perform" rating for the company in a research note on Thursday, October 24th. Bank of America increased their target price on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a "buy" rating in a report on Monday, September 16th. Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a research report on Monday, October 14th. They set a "buy" rating and a $680.00 price target for the company. Robert W. Baird decreased their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating for the company in a research report on Thursday, October 24th. Finally, Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating for the company in a research report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus price target of $649.33.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the sale, the chief executive officer now owns 121,192 shares in the company, valued at $67,175,513.68. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now owns 16,663 shares in the company, valued at $9,333,946.08. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,150 shares of company stock valued at $15,676,125 in the last ninety days. Insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Stock Performance

TMO stock traded down $5.64 during midday trading on Monday, hitting $546.10. The company's stock had a trading volume of 705,786 shares, compared to its average volume of 1,457,621. The stock's 50-day moving average price is $593.95 and its 200 day moving average price is $583.73. The stock has a market cap of $208.88 billion, a price-to-earnings ratio of 34.59, a PEG ratio of 3.65 and a beta of 0.79. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 1 year low of $439.11 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company had revenue of $10.60 billion during the quarter, compared to analysts' expectations of $10.63 billion. During the same period in the prior year, the business posted $5.69 EPS. Thermo Fisher Scientific's quarterly revenue was up .2% compared to the same quarter last year. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.29%. The ex-dividend date is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio is presently 9.78%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.